Blood Pressure and Cardiovascular Effects of Bremelanotide in Hypertensive Versus Normotensive Women
Portman DJ, Clayton AH, Kingsberg SA, et al.
Journal of Sexual Medicine, 2021 · n = 156
Key finding
Systolic BP increased mean 2.3 mmHg with bremelanotide; contraindication in uncontrolled hypertension justified by mean BP increase and tachycardia.
Summary
Safety analysis from Phase 3 trials examining cardiovascular effects in women with and without hypertension history.
Read the study
The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.
View on PubMedRelated compound
More research on PT-141
Comparison of PT-141 and Flibanserin for Female Sexual Desire Disorder: An Indirect Treatment Comparison
Sexual Medicine Reviews · 2022 · Review
Long-Term Safety and Efficacy of Bremelanotide: 1-Year Extension Study in Women with HSDD
The Journal of Sexual Medicine · 2021 · Human Pilot
RECONNECT-1: A Randomized Controlled Trial of Bremelanotide for Female Sexual Desire Disorder
The Journal of Sexual Medicine · 2020 · Human RCT
RECONNECT-2: Phase 3 Trial of Bremelanotide in Premenopausal Women with Generalized Hypoactive Sexual Desire Disorder
The Journal of Sexual Medicine · 2020 · Human RCT
Skin Hyperpigmentation with Melanocortin-4 Receptor Agonists: Predictors and Prevention
The Journal of Sexual Medicine · 2020 · Human Pilot